Detalhe da pesquisa
1.
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.
Blood
; 141(9): 996-1006, 2023 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108341
2.
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Lancet
; 402(10409): 1272-1281, 2023 10 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708904
3.
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
Gastric Cancer
; 27(3): 558-570, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38308771
4.
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.
Lancet Oncol
; 24(7): 744-756, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37329891
5.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(11): 1181-1195, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37875143
6.
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Br J Cancer
; 128(1): 30-41, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36335217
7.
Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer.
Oncologist
; 28(12): e1209-e1218, 2023 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37597246
8.
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
Lancet Oncol
; 23(11): 1430-1440, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36244398
9.
Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment.
Br J Clin Pharmacol
; 88(7): 3392-3403, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35236002
10.
Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study.
Future Oncol
; 18(27): 3011-3020, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35920133
11.
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.
Future Oncol
; 18(12): 1449-1459, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35040698
12.
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
Lancet Oncol
; 22(1): 118-131, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33387490
13.
Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.
Cancer
; 127(6): 884-893, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33197285
14.
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
Oncologist
; 26(10): e1704-e1729, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34288262
15.
Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer.
Oncologist
; 26(3): e414-e424, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33274542
16.
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
Invest New Drugs
; 39(1): 182-192, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32910338
17.
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.
Gastric Cancer
; 24(6): 1330-1340, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34363528
18.
How quality of life can inform management decisions in later-line metastatic colorectal cancer.
Clin Adv Hematol Oncol
; 19 Suppl 22(10): 1-16, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35289802
19.
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
Lancet Oncol
; 21(9): 1234-1243, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32818466
20.
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
Oncologist
; 25(11): 954-962, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32812320